Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view

Clin Colorectal Cancer. 2014 Sep;13(3):e13-5. doi: 10.1016/j.clcc.2014.06.003. Epub 2014 Jun 26.

Authors

Sofia Battisti¹, Francesco Maria Guida², Elisa Pagliara³, Giuseppe Tonini², Bruno Beomonte Zobel³, Daniele Santini²

Affiliations

¹ Department of Radiology, Campus Bio-Medico University of Rome, Rome, Italy. Electronic address: sofia.battisti@hotmail.it.
² Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
³ Department of Radiology, Campus Bio-Medico University of Rome, Rome, Italy.

PMID: 25085312
DOI: 10.1016/j.clcc.2014.06.003

No abstract available

Keywords: Anti-EGFR therapy; CT scan; Neoadjuvant therapy; Toxicity; mCRC.

Publication types

Case Reports

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / secondary
Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Capecitabine
Cetuximab
Chemotherapy, Adjuvant
Colonic Neoplasms / pathology*
Deoxycytidine / administration & dosage
Deoxycytidine / adverse effects
Deoxycytidine / analogs & derivatives
ErbB Receptors / antagonists & inhibitors*
Fluorouracil / administration & dosage
Fluorouracil / adverse effects
Fluorouracil / analogs & derivatives
Humans
Leucovorin / administration & dosage
Liver Cirrhosis / chemically induced*
Liver Neoplasms / drug therapy*
Liver Neoplasms / secondary
Male
Neoadjuvant Therapy
Organoplatinum Compounds / administration & dosage
Organoplatinum Compounds / adverse effects
Oxaliplatin

Substances

Antibodies, Monoclonal, Humanized
Organoplatinum Compounds
Oxaliplatin
Deoxycytidine
Bevacizumab
Capecitabine
ErbB Receptors
Cetuximab
Leucovorin
Fluorouracil
Camptothecin

Supplementary concepts

IFL protocol